Sources of Funding: This study was self-funded.
Interleukin-31: its role in canine pruritus and naturally occurring canine atopic dermatitis
Article first published online: 19 JAN 2013
© 2013 Pfizer Inc. Veterinary Dermatology © 2013 ESVD and ACVD
Volume 24, Issue 1, pages 48–e12, February 2013
How to Cite
Gonzales, A. J., Humphrey, W. R., Messamore, J. E., Fleck, T. J., Fici, G. J., Shelly, J. A., Teel, J. F., Bammert, G. F., Dunham, S. A., Fuller, T. E. and McCall, R. B. (2013), Interleukin-31: its role in canine pruritus and naturally occurring canine atopic dermatitis. Veterinary Dermatology, 24: 48–e12. doi: 10.1111/j.1365-3164.2012.01098.x
Conflict of Interest: All authors are Pfizer Inc. shareholders.
- Issue published online: 19 JAN 2013
- Article first published online: 19 JAN 2013
- Accepted 4 July 2012
Figure S1. Amino acid sequence of the canine IL-31 construct. The identity of purified canine IL-31 protein was confirmed using mass spectrometry to analyze a tryptic digest of the protein and also by N-terminal sequencing.
Figure S2. Detection of phospho-Akt in IL-31-treated DH82 cells. Using Western blotting techniques, phospho-Akt levels were evaluated in DH82 cells treated with varying concentrations of IL-31 (0–10 ug/mL).
Table S1. Individual IL-31 serum levels in dogs with atopic dermatitis. Protein levels of IL-31 were measured in serum using immunoassay techniques in client-owned animals diagnosed with atopic dermatitis. Quantitative levels of IL-31 in serum are listed for each dog evaluated.
|VDE_1098_sm_FigS1-S2-TableS1.docx||53K||Supporting info item|
Please note: Wiley-Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.